Sofie Layton joins Ethics Talk to discuss her article, coauthored with Drs Jo Wray, Victoria Walsh, and Giovanni Biglino: “What Arts-and-Health Practices Teach Us About Participation, Re-presentation, and Risk.”
The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves.
Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Chromosomal microarray analysis reveals many gene variants of unknown significance. The uncertainty about these variants—might they be deleterious or are they benign?—complicates genetic counseling.
Ruth M. Farrell, MD, MA, Holly Pederson, MD, and Shilpa Padia, MD
Though they claim to, direct-to-consumer genetic tests may not correctly identify an individual's ancestral background, and thus may overstate or understate one's risk for heritable disease.
J. Brian Szender, MD, MS and Shashikant B. Lele, MD
The estimated reduction in risk of ovarian cancer for any woman undergoing opportunistic removal of the Fallopian tubes is up to 50 percent, but whether removal is more beneficial than ligation has not been established.
AMA J Ethics. 2015;17(9):843-848. doi:
10.1001/journalofethics.2015.17.9.stas1-1509.